NCT02697058 - Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

May 4, 2017

Study Completion Date

August 28, 2018

Conditions

Metastatic Pancreatic Cancer

Interventions

BIOLOGICAL

BAX2398 + 5-FU/calcium levofolinate

BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate

DRUG

5-FU/calcium levofolinate

5-FU/calcium levofolinate alone

Trial Locations (16)

036-8563

Hirosaki University School of Medicine & Hospital, Hirosaki-shi

260-8717

Chiba Cancer Center, Chiba

277-8577

National Cancer Center Hospital East, Kashiwa-shi

791-0280

NHO Shikoku Cancer Center, Matsuyama

811-1395

NHO Kyushu Cancer Center, Fukuoka

812-8582

Kyushu University Hospital, Fukuoka

060-8648

Hokkaido University Hospital, Sapporo

232-0024

Yokohama City University Medical Center, Yokohama

241-8515

Kanagawa Cancer Center, Yokohama

606-8507

Kyoto University Hospital, Kyoto

540-0006

NHO Osaka National Hospital, Osaka

541-8567

Osaka International Cancer Institute, Osaka

362-0806

Saitama Cancer Center, Kitaadachi-gun

104-0045

National Cancer Center Hospital, Chuo Ku

135-8550

Cancer Institute Hospital of JFCR, Kōtoku

181-8611

Kyorin University Hospital, Mitaka-shi

All Listed Sponsors

collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER